Patient Guide: COR3003/A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at multiple participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTCOR3003
Status: 🟢 Enrolling Now
Condition: Colorectal Cancer
Phase: PHASE3

Loading interactive enrollment tools...

The full interactive experience will load momentarily